

Application No. 10/018,189

AMENDMENTS TO THE CLAIMS

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier. Those claims not cancelled or withdrawn but amended by the current amendment utilize the following notations for amendment: 1. deleted matter is shown by strikethrough for six or more characters and double brackets for five or less characters; and 2. added matter is shown by underlining.

1. (Withdrawn) A composition for treating hyperglycemia in a human or non-human animal comprising one or more compounds selected from the group consisting of: fish protein, hydrolysed fish protein and fish protein amino acids.
2. (Withdrawn) A composition for treating insulin resistance in a human or non-human animal comprising one or more compounds selected from the group consisting of: fish protein, hydrolysed fish protein and fish protein amino acids.
3. (Withdrawn) A composition as defined in claim 1, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.
4. (Withdrawn) A composition as defined in claim 1, wherein said fish protein is code fish protein.
5. (Withdrawn) A composition as defined in claim 4, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
6. (Canceled).

Application No. 10/018,189

7. (Withdrawn) Use of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids to prevent or treat hyperglycemia.
8. (Withdrawn) Use of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids to prevent or treat obesity complications, which may include arteriosclerosis, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, hypertension and hyperinsulinemia.
9. (Withdrawn) Use of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids to produce a medicament to restore normal insulin function in an insulin-resistant mammal.
10. (Withdrawn) Use of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids to produce a medicament to prevent or treat hyperglycemia.
11. (Withdrawn) Use of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids to produce a medicament to prevent or treat obesity complications, which may include arteriosclerosis, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, hypertension and hyperinsulinemia.
12. (Withdrawn) A use as defined in claim 6, wherein said fish protein is cod fish protein.
13. (Currently Amended) A method ~~of preventing or treating insulin resistance in a human or non-human animal suffering therefrom,~~ for potentiating normal or deficient insulin function on glucose metabolism in a mammal when measured on an intravenous glucose tolerance test, said method comprising the administration of an effective amount of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids.

Application No. 10/018,189

14. (Withdrawn) A method of preventing or treating hyperglycemia in a human or non-human animal, comprising the administration of an effective amount of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids.

15. (Withdrawn) A method of preventing or treating obesity complications in a human or non-human animal, which may include arteriosclerosis, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, hypertension and hyperinsulinemia, comprising the administration of an effective amount of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids.

16. (Currently Amended) A method, as defined in claim 13, wherein said one or more compounds is administered ~~of preventing or treating insulin resistance in a human or non human animal comprising the consumption of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids in a quantity that is about 4% to about 60% of said animal's~~ the mammal's diet.

17. (Withdrawn) A method of preventing or treating hyperglycemia in a human or non-human animal comprising the consumption of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids in a quantity that is about 4% to about 60% of said animal's diet.

18. (Withdrawn) A method of preventing or treating obesity in a human or non-human animal comprising the consumption of one of more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids in a quantity that is about 4% to about 60% of said animal's diet.

19. (Currently Amended) A method as defined in claim 13, wherein said deficient insulin function is caused by ~~resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.~~

Application No. 10/018,189

20. (Currently Amended) A method as defined in claim 13, wherein said fish protein is cod [[fish]] protein.
21. (Previously Presented) A method as defined in claim 20, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
22. (Withdrawn) A composition for treating hyperglycemia in a human or non-human animal comprising a mixture of one or more amino acids in the following weight proportion (units of amino acid/100 units of total amino acids): about 6.74 alanine; about 6.29 arginine; about 11.14 aspartic acid; about 16.75 about glutamic acid; about 5.39 glycine; about 2.27 histidine; about 3.24 isoleucine; about 8.31 leucine; about 1.98 methionine; about 9.41 lysine; about 4.22 phenylalanine; about 4.42 proline; about 5.55 serine; about 4.84 threonine; about 4.31 tyrosine; and about 3.86 valine.
23. (Withdrawn) A composition for treating insulin resistance in a human or non-human animal comprising a mixture of one or more amino acids in the following weight proportion (units of amino acid/100 units of total amino acids): about 6.74 alanine; about 6.29 arginine; about 11.14 aspartic acid; about 16.75 about glutamic acid; about 5.39 glycine; about 2.27 histidine; about 3.24 isoleucine; about 8.31 leucine; about 1.98 methionine; about 9.41 lysine; about 4.22 phenylalanine; about 4.42 proline; about 5.55 serine; about 4.84 threonine; about 4.31 tyrosine; and about 3.86 valine.
24. (Withdrawn) A composition as defined in claim 22, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.
25. (Withdrawn) A composition as defined in claim 22, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
26. (Currently Amended) A method, as defined in claim 13, wherein said ~~of preventing or treating insulin resistance in a human or non human animal suffering therefrom, comprising the~~

Application No. 10/018,189

~~administration of an effective amount of a mixture of one or more amino acids~~ comprise ~~[[in]]~~ the following weight proportion ~~(units of amino acid/100 units of total amino acids)~~: about 6.74 alanine per 100 units of total amino acids; about 6.29 arginine per 100 units of total amino acids; about 11.14 aspartic acid per 100 units of total amino acids; about 16.75 glutamic acid per 100 units of total amino acids; about 5.39 glycine per 100 units of total amino acids; about 2.27 histidine per 100 units of total amino acids; about 3.24 isoleucine per 100 units of total amino acids; about 8.31 leucine per 100 units of total amino acids; about 1.98 methionine per 100 units of total amino acids; about 9.41 lysine per 100 units of total amino acids; about 4.22 phenylalanine per 100 units of total amino acids; about 4.42 proline per 100 units of total amino acids; about 5.55 serine per 100 units of total amino acids; about 4.84 threonine per 100 units of total amino acids; about 4.31 tyrosine per 100 units of total amino acids; and about 3.86 valine per 100 units of total amino acids.

27. (Withdrawn) A method of preventing or treating hyperglycemia in a human or non-human animal, comprising the administration of an effective amount of a mixture of one or more amino acids in the following weight proportion (units of amino acid/100 units of total amino acids): about 6.74 alanine; about 6.29 arginine; about 11.14 aspartic acid; about 16.75 about glutamic acid; about 5.39 glycine; about 2.27 histidine; about 3.24 isoleucine; about 8.31 leucine; about 1.98 methionine; about 9.41 lysine; about 4.22 phenylalanine; about 4.42 proline; about 5.55 serine; about 4.84 threonine; about 4.31 tyrosine; and about 3.86 valine.

28. (Withdrawn) A method of preventing or treating obesity complications in a human or non-human animal, which may include arteriosclerosis, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, hypertension and hyperinsulinemia, comprising the administration of an effective amount of a mixture of one or more amino acids in the following weight proportion (units of amino acid/100 units of total amino acids): about 6.74 alanine; about 6.29 arginine; about 11.14 aspartic acid; about 16.75 about glutamic acid; about 5.39 glycine; about 2.27 histidine; about 3.24 isoleucine; about 8.31 leucine; about 1.98 methionine; about 9.41 lysine; about 4.22 phenylalanine; about 4.42 proline; about 5.55 serine; about 4.84 threonine; about 4.1 tyrosine; and about 3.86 valine.

Application No. 10/018,189

29. (Currently Amended) A method as defined in claim 26, wherein said deficient insulin resistance function is caused by ~~[[or]] hyperglycemia is the result of Type 1 or Type 2 diabetes.~~
30. (Previously Presented) A method as defined in claim 29, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
31. (Withdrawn) A composition as defined in claim 2, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.
32. (Withdrawn) A composition as defined in claim 2, wherein said fish protein is cod fish protein.
33. (Withdrawn) A composition as defined in claim 3, wherein said fish protein is cod fish protein.
34. (Withdrawn) A composition as defined in claim 31, wherein said fish protein is cod fish protein.
35. (Withdrawn) A use as defined in claim 7, wherein said fish protein is cod fish protein.
36. (Withdrawn) A use as defined in claim 8, wherein said fish protein is cod fish protein.
37. (Withdrawn) A use as defined in claim 9, wherein said fish protein is cod fish protein.
38. (Withdrawn) A use as defined in claim 10, wherein said fish protein is cod fish protein.
39. (Withdrawn) A use as defined in claim 11, wherein said fish protein is cod fish protein.

Application No. 10/018,189

40. (Withdrawn) A method as defined in claim 14, wherein said insulin resistance of hyperglycemia is the result of type 1 or Type 2 diabetes.

41. (Currently Amended) A method as defined in claim ~~[[16]]~~ 13, wherein said ~~insulin resistance~~ or hyperglycemia is the result of Type 1 or Type 2 diabetes.

42. (Withdrawn) A method as defined in claim 17, wherein said insulin resistance or hyperglycemia is the result of type 1 or Type 2 diabetes.

43. (Withdrawn) A method as defined in claim 14, wherein said fish protein is cod fish.

44. (Withdrawn) a method as defined in claim 15, wherein said fish protein is cod fish.

45. (Currently Amended) A method as defined in claim ~~[[16]]~~ 29, ~~wherein said fish protein is cod fish~~ wherein said hyperglycemia is the result of Type 1 or Type 2 diabetes.

46. (Withdrawn) A method as defined in claim 17, wherein said fish protein is cod fish.

47. (Withdrawn) A method as defined in claim 18, wherein said fish protein is cod fish.

48. (Currently Amended) A method as defined in claim 19, wherein said fish protein is cod ~~[[fish]]~~ protein.

49. (Withdrawn) A method as defined in claim 40, wherein said fish protein is cod fish.

50. (Currently Amended) A method as defined in claim 41, wherein said fish protein is cod ~~[[fish]]~~ protein.

51. (Withdrawn) A method as defined in claim 42, wherein said fish protein is cod fish.

Application No. 10/018,189

52. (Withdrawn) A composition as defined in claim 23, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.
53. (Withdrawn) A composition as defined in claim 23, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
54. (Withdrawn) A composition as defined in claim 24, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
55. (Withdrawn) A composition as defined in claim 52, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
56. (Withdrawn) A method as defined in claim 27, wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.
57. (Withdrawn) A method as defined in claim 28, wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.
58. (Withdrawn) A method as defined in claim 56, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
59. (Withdrawn) A method as defined in claim 57, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
60. (Withdrawn) A composition as defined in claim 32, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
61. (Withdrawn) A composition as defined in claim 33, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.



Application No. 10/018,189

62. (Withdrawn) A composition as defined in claim 34, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.
63. (Withdrawn) A method as defined in claim 43, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
64. (Withdrawn) A method as defined in claim 43, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
65. (Previously Presented) A method as defined in claim 45, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
66. (Withdrawn) A method as defined in claim 46, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
67. (Withdrawn) A method as defined in claim 47, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
68. (Previously Presented) A method as defined in claim 48, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
69. (Withdrawn) A method as defined in claim 49, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
70. (Previously Presented) A method as defined in claim 50, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.
71. (Withdrawn) A method as defined in claim 51, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

Application No. 10/018,189

Please add the following new claim:

72. (New) A method, as defined in claim 13, wherein said deficient insulin function is caused by obesity.